{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=82", "query": { "condition": "Recurrent Neoplasm", "page": 82 }, "page_size": 10 }, "pagination": { "page": 82, "page_size": 10, "total_count": 9123, "total_pages": 913, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=83&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=81&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T22:11:05.273Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00671112", "title": "Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "714leukemia", "Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brian Hill, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-11-10T22:11:05.273Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671112" }, { "nct_id": "NCT00669019", "title": "Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IIA Melanoma", "Stage IIB Melanoma", "Stage IIC Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "saracatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2006-07", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2014-05-21", "last_synced_at": "2026-11-10T22:11:05.273Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00669019" }, { "nct_id": "NCT00003765", "title": "O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "O6-benzylguanine", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 36, "start_date": "1999-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-05", "last_synced_at": "2026-11-10T22:11:05.273Z", "location_count": 51, "location_summary": "Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 40 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003765" }, { "nct_id": "NCT00014144", "title": "S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Transitional Cell Cancer of the Renal Pelvis and Ureter", "Urethral Cancer" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 31, "start_date": "2001-02", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2012-10-08", "last_synced_at": "2026-11-10T22:11:05.273Z", "location_count": 95, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014144" }, { "nct_id": "NCT02811809", "title": "Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "IHT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2020-12", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2020-02-27", "last_synced_at": "2026-11-10T22:11:05.273Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02811809" }, { "nct_id": "NCT00780598", "title": "Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "AML" ], "interventions": [ { "name": "Tosedostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chroma Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 76, "start_date": "2009-10", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2012-06-28", "last_synced_at": "2026-11-10T22:11:05.273Z", "location_count": 17, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00780598" }, { "nct_id": "NCT04059393", "title": "PCRC-Supported Legacy Intervention in Pediatric Palliative Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Care Giver", "Recurrent Malignant Neoplasm", "Refractory Malignant Neoplasm" ], "interventions": [ { "name": "Internet-Based Intervention", "type": "OTHER" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "7 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "7 Years to 17 Years" }, "enrollment_count": 300, "start_date": "2015-07-27", "completion_date": "2018-06-05", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-11-10T22:11:05.273Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04059393" }, { "nct_id": "NCT00387933", "title": "Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "hydroxyurea", "type": "DRUG" }, { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "vatalanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2005-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-14", "last_synced_at": "2026-11-10T22:11:05.273Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00387933" }, { "nct_id": "NCT00738452", "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "high performance liquid chromatography", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "radionuclide imaging", "type": "PROCEDURE" }, { "name": "single photon emission computed tomography", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "yttrium Y 90 anti-CEA monoclonal antibody cT84.66", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2008-10-13", "completion_date": "2018-02-07", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-10T22:11:05.273Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00738452" }, { "nct_id": "NCT01683149", "title": "Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 13, "start_date": "2013-01", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-03-04", "last_synced_at": "2026-11-10T22:11:05.273Z", "location_count": 9, "location_summary": "Los Angeles, California • Hartford, Connecticut • Wilmington, Delaware + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01683149" } ] }